Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL Line from a Japanese metastatic melanoma patient

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 647-655

  Akiyama, Yasuto ^a   Maruyama, Kouji ^a   Tai, Sachiko ^a   Komiyama, Masaru ^a   Iizuka, Akira ^a   Takikawa, Asako ^a   Ohshita, Chie ^a   Yamamoto, Akifumi ^b   Yamazaki, Naoya ^c   Kiyohara, Yoshio ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

DC vaccine; Electroporation; MAGE1 HLA A24 restricted peptide; Metastatic melanoma; T cell receptor (TCR) beta cDNA cloning

Indexed keywords

COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; EPITOPE; HLA A24 ANTIGEN; MELANOMA ANTIGEN 1; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TETRAMER;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; JAPANESE; MELANOMA; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; DNA, COMPLEMENTARY; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 61449231869     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rosenberg SA, Yang JC and Restifo NP: Cancer immuotherapy: moving beyond current vaccine. Nat Med 10: 909-915, 2004.
2. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
3. Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K and Kato I: Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocytes. Int J Cancer 80: 92-97, 1999.
4. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL and Deleo AB: A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinoma of the head and neck. Clin Cancer Res 6: 979-986, 2000.
5. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E and Akiyoshi T: Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocyte antigen-A24. Cancer Res 57: 4465-4468, 1997.
6. Wada S, Tssunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 65: 4936-4946, 2005.
7. Akiyama Y, Tanosaki R, Inoue N, Shimada M, Hotate Y, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K, Maruyama K, Takaue Y and Yamaguchi K: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3: 4, 2005.
8. Kikuchi M, Nakao M, Inoue, Matsunaga K, Shichijo S, Yamana H and Itoh K: Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 81: 459-466, 1999
9. Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K and Itoh K: A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 163: 4994-5004, 1999.
10. Akiyama Y, Maruyama K, Nara N, Mochizuki T, Yamamoto A, Yamazaki N, Kawashima I, Nukaya I, Takesako K and Yamaguchi K: Cytotoxic T-cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res 24: 571-577, 2004.
11. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T-cells. Cancer Immunol Immunother 50: 3-15, 2001.
12. + T-cells in melanoma patients. J Immunol 165: 533-538, 2000.
13. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T, Brichard V, Boon T, Bordignon C, Anichini A and Parmiani G: Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 92: 5674-5678, 1995.
14. + T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 27: 36-47, 2004.
15. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B, Connerotte T, Corbiere V, Demoitie MA, Lienard D, Dreno B, Velu T, Boon T and Coulie PG: Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171: 4898-4904, 2003.
16. + cytotoxic T lymphocytes. Int J Cancer 87: 553-558, 2000.
17. Sili U, Huls MH, Davis AR, Brenner MK, Heslop H and Rooney CM: Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother 26: 241-256, 2003.
18. Yajima N, YamanakaR, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K and Tanaka R: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900-5911, 2005.
19. Komori H, Nakatsura T, Senju S, Yoshitaka Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H and Nishimura Y: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
20. Azuma T, Makita M, Ninomiya K, Fujita S, Harada M and Yasikawa M: Identification of a novel WT1-derived peptide which induced human leukocyte antigen-A24-restricted anti-leukemia cytotoxic T lymphocytes. Br J Haematol 116: 601-603, 2002.
21. Okumura H, Noguchi Y, Uenaka A, Aji T, Ono T, Nakagawa K, Aoe M, Shimizu N and Nakayama E: Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiol Immunol 49: 1009-1016, 2005.
22. So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T and Coulie PG: Lack of tumor recognition by cytotoxic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 56: 259-269, 2007.
23. Lu J, Leng X, Peng J and Weifeng C: Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 MAGE-1 peptide. Chin Med J 115: 1002-1005, 2002.
24. Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H and Yamagishi H: Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol 37: 140-145, 2007.
25. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A and Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23: 2346-2357, 2005.